What is already known about this topic?
Meningococcal disease is a life-threatening invasive infection caused by Neisseria meningitidis. MenB-4C (Bexsero, GSK), one of two licensed meningococcal serogroup B vaccines, protects against serogroup B N. meningitidis and is licensed for persons aged 10–25 years.
What is added by this report?
On October 24, 2024, the Advisory Committee on Immunization Practices (ACIP) updated its recommendations for MenB-4C to align the dosing interval and schedule with the new Food and Drug Administration (FDA) label and harmonize with recommendations for MenB-FHbp (Trumenba, Pfizer, Inc.) vaccine. ACIP now recommends MenB-4C as a 2-dose series with doses administered at intervals of 0 and 6 months for healthy adolescents and young adults aged 16–23 years based on shared clinical decision-making and as a 3-dose series with doses administered at 0, 1–2, and 6 months for persons aged ≥10 years at increased risk.
What are the implications for public health practice?
The new MenB-4C dosing interval and schedule improves immune protection. ACIP recommendations for the MenB-4C dosing interval and schedule are now aligned with the updated FDA label and are harmonized with ACIP recommendations for use of MenB-FHbp.
- Recommendation
- Americas
- United States of America
- Meningococcal disease
